Atara Biotherapeutics, Inc. (0HIY.L)
| Previous close | 6.91 |
| Open | 6.55 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 6.55 - 6.91 |
| 52-week range | 6.55 - 6.91 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 174.707M |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.64 |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Atara Biotherapeutics (NASDAQ:ATRA) shareholders are up 17% this past week, but still in the red over the last three years
This week we saw the Atara Biotherapeutics, Inc. ( NASDAQ:ATRA ) share price climb by 17%. But only the myopic could...
- Business Wire
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress
SOUTH SAN FRANCISCO, Calif., June 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced EMA regulatory progress and tabelecleucel (tab-cel®) clinical outcomes. Data is reported from the multicenter Expanded Access Program (EAP) study in Europe for patients with relapsed or refractory (r/r) Epstein-Barr virus-dr
- Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 03, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 126,928 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 186,378 shares of Atara’s common stock to three such newly hired
